AngioDynamics cuts FY24 revenue guidance to $320-325M; Q2 revenue $79.1M, Auryon sales up 12.9%

ANGIODYNAMICS INC

2024-Q2 EPS reported $0.42 revenue$157,752,000

FY24 revenue guidance lowered to $320M-$325M from $328M-$333M; adjusted EPS loss widens to ($0.35)-($0.42) from ($0.28)-($0.34).
Q2 FY24 pro forma revenue $79.1M, growth 2.7%; Med Tech +3.5%, Auryon sales $11.4M (+12.9% YoY).
PRESERVE (NanoKnife) and APEX AV (AlphaVac PE) studies fully enrolled; FDA submission for PE planned early 2024.
Cumulative Auryon sales exceeded $100M; CE Mark for Auryon and AlphaVac expected 1H 2024.
Full-year adjusted EPS profitability expected in FY27; manufacturing restructuring to fully outsourced model initiated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.